Luke Nathaniel Walker Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

Luke Nathaniel Walker is Director of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 86,681 shares of ZNTL, which is worth approximately $162,093. The most recent transaction as insider was on Jan 31, 2025, when has been sold 14,200 shares (Common Stock) at a price of $1.76 per share, resulting in proceeds of $24,992. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 86.7K

19.59% 3M change

n/a 12M change

Total Value Held $162,093

Luke Nathaniel Walker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Jan 31 2025	BUY Open market or private purchase	$24,992 $1.76 p/Share	14,200 Added 14.08%	86,681 Common Stock
May 24 2024	BUY Grant, award, or other acquisition	-	72,481 Added 50.0%	72,481 Common Stock

Also insider at

HARP

Harpoon Therapeutics, Inc. Healthcare

Chief Medical Officer

CNTX

Context Therapeutics Inc. Healthcare

Director

LNW